

Early and locally advanced breast cancer (update) Committee meeting 9

Date: 9 October 2017

Location: RCOG, London

Minutes: Confirmed

Committee members present:	
Jane Barrett (Chair)	(Present for items 1 – 6)
Anne Armstrong (Topic Advisor)	(Present for items 1 – 6)
Faye Coe	(Present for items 1 – 6)
Ramsey Cutress	(Present for items 1 – 6)
Carmel Gulliver-Clarke	(Present for items 1 – 6)
Sadaf Haque	(Present for items 1 – 6)
Roger Hunt	(Present for items 1 – 6)
Peter Jenkins	(Present for items 1 – 6)
Imogen Locke	(Present for items 1 – 6)
Marina Parton	(Present for items 1 – 6)
Mia Rosenblatt	(Present for items 1 – 6)(via VC)
William Teh	(Present for items 1 – 5)
Ursula Van Mann	(Present for items 1 – 5)
Lisa Whisker	(Present for items 1 – 6)
Sairanne Wickers	(Present for items 1 – 6)

In attendance:		
Sarah Palombella	NICE Senior Medical Editor	(Present for items 1 – 6)
Adam Storrow	NICE Business Analyst	(Present for items 1 – 5)
Nathan Bromham	NGA Senior Systematic Reviewer	(Present for items 1 – 6)
Hilary Eadon	NGA Guideline Lead	(Present for items 1 – 6)
John Graham	NGA Clinical Advisor	(Present for items 1 – 6)(via VC)
Sally Humphreys	NGA Project Manager	(Present for items 1 – 6)
Laura O’Shea	NGA Systematic Reviewer	(Present for items 1 – 6)
Anuja Pandey	NGA Systematic Reviewer	(Present for items 1 – 5)
Matthew Prettyjohns	NGA Senior Health Economist	(Present for items 1 – 5)(via VC)

Gemma Villanueva	NGA Senior Systematic Reviewer	(Present for items 5 – 6)
------------------	--------------------------------	---------------------------

Apologies:

Linda Pepper	GC member
Andrew Harding	NICE Guideline Commissioning Manager
Elise Hasler	NGA Information Scientist

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the ninth meeting on Early and locally advanced breast cancer (update).

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting which included reviewing the evidence and drafting recommendations for questions 8.1 and 10.1, reviewing the draft economic model for question 5.1, and considering the NICE editor’s proposed wording amendments to the recommendations drafted to date, and refreshing recommendations for areas which are not being reviewed as part of this guideline update.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Early and locally advanced breast cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Ramsey Cuttress	Consultant Surgeon and Associate Professor, Cancer Sciences Unit, Southampton General Hospital	9.10.2017 Provided expert input into a MHRA regulatory discussion on the use of the anticancer medicine	Personal financial specific	Declare and participate, expenses received not beyond reasonable amounts

		tamoxifen in a chemopreventative indication for breast cancer. Only travelling and subsistence expenses received.		
Imogen Locke	Consultant Clinical Oncologist, Royal Marsden NHS Foundation Trust	9.10.2017 Co-author on a paper for assessing voluntary breath holding as a heart sparing radiotherapy technique.	Personal non-financial specific	Declare and withdraw from discussions on recommendations for review question 8.1
Marina Parton	Consultant Medical Oncologist, Royal Marsden and Kingston NHS Trusts	9.10.2017 Teaching session at Royal College of Physicians September 2017 sponsored by Eisai, pharmaceutical who make drugs for metastatic breast cancer. Paid honoraria	Personal financial specific	Withdraw from discussion of any interventions made by Eisai

Due to a potential conflict of interests Imogen Locke withdrew from discussion on the recommendations for review question 8.1.

3. Minutes of last meeting

The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate

account of the meeting.

4. Presentations

The Chair introduced Anuja Pandey, NGA Systematic Reviewer, who gave a presentation on the evidence for review question 8.1 What radiotherapy techniques are effective for excluding the heart from the radiation field without compromising coverage of the whole breast target volume for people with early or locally advanced breast cancer?

The Chair introduced Nathan Bromham, NGA Senior Systematic Reviewer, who gave a presentation on the evidence for review question Review question 10.1 What is the effectiveness of neoadjuvant chemotherapy?

The Chair introduced Matthew Prettyjohns, NGA Senior Health Economist, who gave a presentation on the economic model for review question 5.1 Which people with early and locally advanced breast cancer would benefit from the incorporation of taxanes in adjuvant chemotherapy?

The Chair introduced Matthew Prettyjohns, NGA Senior Health Economist, who gave a presentation on the economic model for review question 7.1 What are the indications for using adjuvant bisphosphonates in people with early and locally advanced breast cancer?

The Chair introduced Gemma Villanueva, NGA Senior Systematic Reviewer, who gave a presentation on updated information on the PREDICT tool in review question 3.2.

The speakers took questions from the group. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked the speakers for their presentations.

5. Questions and discussion

The Committee discussed the evidence for review questions and agreed recommendations and content for the sections linking the evidence to recommendations.

The Committee discussed the economic model for questions 5.1 and the results of the model and the recommendations for question 7.1.

The Committee then reviewed the NICE editor's comments on the recommendations that had been drafted previously and on the refreshed language of the recommendations from guideline chapters which were not being updated.

6. Any other business

The dates for the progress of the guideline were outlined.

Date of next meeting: 9-10 November 2017

Location of next meeting: RCOG, London